These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 31474633)
21. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Chow MD; Lee YH; Guo GL Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273 [TBL] [Abstract][Full Text] [Related]
23. Different Effects of Eicosapentaenoic and Docosahexaenoic Acids on Atherogenic High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice. Suzuki-Kemuriyama N; Matsuzaka T; Kuba M; Ohno H; Han SI; Takeuchi Y; Isaka M; Kobayashi K; Iwasaki H; Yatoh S; Suzuki H; Miyajima K; Nakae D; Yahagi N; Nakagawa Y; Sone H; Yamada N; Shimano H PLoS One; 2016; 11(6):e0157580. PubMed ID: 27333187 [TBL] [Abstract][Full Text] [Related]
24. Effects of Nonalcoholic Fatty Liver Disease on Hepatic CYP2B1 and in Vivo Bupropion Disposition in Rats Fed a High-Fat or Methionine/Choline-Deficient Diet. Cho SJ; Kim SB; Cho HJ; Chong S; Chung SJ; Kang IM; Lee JI; Yoon IS; Kim DD J Agric Food Chem; 2016 Jul; 64(27):5598-606. PubMed ID: 27321734 [TBL] [Abstract][Full Text] [Related]
25. The indole derivative NecroX-7 improves nonalcoholic steatohepatitis in ob/ob mice through suppression of mitochondrial ROS/RNS and inflammation. Chung HK; Kim YK; Park JH; Ryu MJ; Chang JY; Hwang JH; Lee CH; Kim SH; Kim HJ; Kweon GR; Kim KS; Shong M Liver Int; 2015 Apr; 35(4):1341-53. PubMed ID: 25443620 [TBL] [Abstract][Full Text] [Related]
26. [A Future Perspective on the Involvement of n-3 Polyunsaturated Fatty Acid in the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis]. Nakamoto K; Obata T; Hirasawa A; Kim KI; Kim SR; Tokuyama S Yakugaku Zasshi; 2016; 136(4):583-9. PubMed ID: 27040343 [TBL] [Abstract][Full Text] [Related]
27. Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans. Cruces-Sande M; Vila-Bedmar R; Arcones AC; González-Rodríguez Á; Rada P; Gutiérrez-de-Juan V; Vargas-Castrillón J; Iruzubieta P; Sánchez-González C; Formentini L; Crespo J; García-Monzón C; Martínez-Chantar ML; Valverde ÁM; Mayor F; Murga C Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3655-3667. PubMed ID: 30261289 [TBL] [Abstract][Full Text] [Related]
28. Polydatin attenuates diet-induced nonalcoholic steatohepatitis and fibrosis in mice. Li R; Li J; Huang Y; Li H; Yan S; Lin J; Chen Y; Wu L; Liu B; Wang G; Lan T Int J Biol Sci; 2018; 14(11):1411-1425. PubMed ID: 30262993 [No Abstract] [Full Text] [Related]
29. Liver-specific loss of Perilipin 2 alleviates diet-induced hepatic steatosis, inflammation, and fibrosis. Najt CP; Senthivinayagam S; Aljazi MB; Fader KA; Olenic SD; Brock JR; Lydic TA; Jones AD; Atshaves BP Am J Physiol Gastrointest Liver Physiol; 2016 May; 310(9):G726-38. PubMed ID: 26968211 [TBL] [Abstract][Full Text] [Related]
30. Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice. Li J; Liu C; Zhou Z; Dou B; Huang J; Huang L; Zheng P; Fan S; Huang C Phytother Res; 2021 Jun; 35(6):3351-3364. PubMed ID: 33784797 [TBL] [Abstract][Full Text] [Related]
31. Nicotinic acetylcholine receptor α7 subunit improves energy homeostasis and inhibits inflammation in nonalcoholic fatty liver disease. Li DJ; Liu J; Hua X; Fu H; Huang F; Fei YB; Lu WJ; Shen FM; Wang P Metabolism; 2018 Feb; 79():52-63. PubMed ID: 29129819 [TBL] [Abstract][Full Text] [Related]
32. IL-1β and TNFα inhibit GPR120 (FFAR4) and stimulate GPR84 (EX33) and GPR41 (FFAR3) fatty acid receptor expression in human adipocytes: implications for the anti-inflammatory action of n-3 fatty acids. Muredda L; Kępczyńska MA; Zaibi MS; Alomar SY; Trayhurn P Arch Physiol Biochem; 2018 May; 124(2):97-108. PubMed ID: 28835131 [TBL] [Abstract][Full Text] [Related]
34. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. Hayashizaki-Someya Y; Kurosaki E; Takasu T; Mitori H; Yamazaki S; Koide K; Takakura S Eur J Pharmacol; 2015 May; 754():19-24. PubMed ID: 25701721 [TBL] [Abstract][Full Text] [Related]
35. Deletion of nardilysin prevents the development of steatohepatitis and liver fibrotic changes. Ishizu-Higashi S; Seno H; Nishi E; Matsumoto Y; Ikuta K; Tsuda M; Kimura Y; Takada Y; Kimura Y; Nakanishi Y; Kanda K; Komekado H; Chiba T PLoS One; 2014; 9(5):e98017. PubMed ID: 24849253 [TBL] [Abstract][Full Text] [Related]
36. Nonalcoholic Fatty Liver Disease Is Exacerbated in High-Fat Diet-Fed Gnotobiotic Mice by Colonization with the Gut Microbiota from Patients with Nonalcoholic Steatohepatitis. Chiu CC; Ching YH; Li YP; Liu JY; Huang YT; Huang YW; Yang SS; Huang WC; Chuang HL Nutrients; 2017 Nov; 9(11):. PubMed ID: 29113135 [TBL] [Abstract][Full Text] [Related]
37. Hepatoprotective and antioxidant activities of extracts from Salvia-Nelumbinis naturalis against nonalcoholic steatohepatitis induced by methionine- and choline-deficient diet in mice. Liu Y; Song H; Wang L; Xu H; Shu X; Zhang L; Li Y; Li D; Ji G J Transl Med; 2014 Nov; 12():315. PubMed ID: 25406833 [TBL] [Abstract][Full Text] [Related]
39. Docosahexaenoic Acid and Its Role in G-Protein-Coupled Receptor 120 Activation in Children Affected by Nonalcoholic Fatty Liver Disease. Della Corte C; Mosca A; Ionata A; Nobili V Endocr Dev; 2016; 30():29-36. PubMed ID: 26683215 [TBL] [Abstract][Full Text] [Related]
40. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Staels B; Rubenstrunk A; Noel B; Rigou G; Delataille P; Millatt LJ; Baron M; Lucas A; Tailleux A; Hum DW; Ratziu V; Cariou B; Hanf R Hepatology; 2013 Dec; 58(6):1941-52. PubMed ID: 23703580 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]